If you have a medical condition you may be eligible to participate in a patient clinical trial for the condition.
The team here at Scientia Clinical Research would love to welcome you on a clinical trial, but first you will need a medical referral letter including all relevant treatment and diagnostic information. You may also speak to your oncology consultant, and they will be able to contact us if you are a suitable candidate for referral.
To facilitate prompt review of referral, please include the following:
- A clinical trial referral letter
- Medical and treatment history
- Most recent blood test and scan results
- Histopathology or biopsy reports
- Molecular pathology result, if available
- Contact details of referring doctor
If you have have any questions please email our team at : ContactUs@scientiaclinicalresearch.com.au
SHR-A1921-I-102-AUS
An open-label, multi-center phase in clinical study on the safety, tolerability, pharmacokinetics, and clinical activity of SHR-A1921 for injection in subjects with advanced solid tumours
Locations
Randwick, Sydney
Category
Advanced Solid Tumours
BAT-6026-001-CR
A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6026 as Monotherapy and in Combination with BAT1308 in Patients with Advanced Solid Tumours
Locations
Randwick, Sydney
Category
Advanced Solid Tumours
ATG-101-001
A First-in-Human Phase I Trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas. “PROBE Study”
Locations
Randwick, Sydney
Category
Advanced Solid Tumours and Mature B-cell NHL
MDNA11-01
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors. “ABILITY Study”
Locations
Randwick, Sydney
Category
Advanced Solid Tumours
SHR2002
A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant Tumors
Locations
Randwick, Sydney
Category
Advanced Solid Tumours
CS5001
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas
Locations
Randwick, Sydney
Category
Advanced Solid Tumours and Lymphomas
CP-MVC-1-1-01
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer
Locations
Randwick, Sydney
Category
Unresectable Locally Advanced or Metastatic Cancer
SHR-A1904-I-10
AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS EXPRESSING CLAUDIN 18.2
Locations
Randwick, Sydney
Category
Advanced Solid Tumours
80948543LYM1001
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL
Locations
Randwick, Sydney
Category
Advanced Solid Tumours
Axelia AXA-042
A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumors.
Locations
Randwick, Sydney
Category
Advanced Solid Tumours
AMX-818-001 – Ammunix
A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of AMX-818 Alone and in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic HER2-Expressing Cancers
Locations
Randwick, Sydney
Category
Locally Advanced or Metastatic HER2-Expressing Cancers
SHR-A1921-I-102
AN OPEN-LABEL, MULTI-CENTER PHASE I CLINICAL STUDY ON THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND CLINICAL ACTIVITY OF SHR-A1921 FOR INJECTION IN SUBJECTS WITH ADVANCED SOLID TUMORS
Locations
Randwick, Sydney
Category
Advanced Solid Tumours
CIBI354A101
A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Locations
Randwick, Sydney
Category
Locally Advanced Unresectable or Metastatic Solid Tumors
THOR-707-101
An open-label, multicenter Phase 1/2 dose escalation and expansion study of THOR-707 as a Single agent and as a combination therapy in adult subjects with advanced or metastatic solid tumors
Locations
Randwick, Sydney
Category
advanced or metastatic solid tumors
PMR-116-101
PMR-116 in Patients with Advanced Malignancies
Locations
Randwick, Sydney
Category
Advanced Malignancies
AK112
A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects with Advanced Solid Tumors
Locations
Randwick, Sydney
Category
Ovarian Cancer
For a complete list of current clinical trials in Australia, please see the below websites:
Australian New Zealand Clinical Trials Registry – https://www.anzctr.org.au/
Clinical Trials. Gov – https://www.clinicaltrials.gov/
Australian Cancer Trials – https://www.clinicaltrials.gov/
We also conduct Healthy Volunteer Clinical trials which may be of interest for people with no medical conditions.
